Amicus Therapeutics Inc

Latest Results (07.10.2025):

Amicus Therapeutics Inc reported its second quarter 2025 financial results, achieving total revenues of $154.7 million, an 18% increase at constant exchange rates (CER). The growth was primarily driven by strong sales of Galafold® and Pombiliti® + Opfolda®. Despite the revenue growth, the company reported a GAAP net loss of $24.4 million, while reaffirming its guidance for reaching GAAP profitability in the second half of 2025.

Total Revenue Growth

In Q2 2025, Amicus Therapeutics' total revenues reached $154.7 million, reflecting an 18% increase at CER compared to the same period last year. This growth was supported by a currency tailwind of $5 million, accounting for a 4% increase.

Product Sales Performance

Galafold® sales totaled $128.9 million in Q2 2025, marking a 12% increase at CER. Meanwhile, Pombiliti® + Opfolda® sales surged by 58% at CER to $25.8 million, driven by high commercial demand and new launches in five countries.

Operating Expenses

GAAP operating expenses for the second quarter of 2025 were $148.9 million, a 48% increase from $100.4 million in Q2 2024. Non-GAAP operating expenses rose by 56% to $127.8 million during the same period, partly due to a $30 million upfront payment for the U.S. licensing agreement of DMX-200.

Net Income

Amicus reported a GAAP net loss of $24.4 million for Q2 2025, compared to a net loss of $15.7 million in Q2 2024. Non-GAAP net income stood at $1.9 million, down from $18.5 million in the previous year.

Cash Position

The company maintained a cash, cash equivalents, and marketable securities balance of $231.0 million as of June 30, 2025, reflecting the $30 million upfront payment for the U.S. licensing agreement of DMX-200.

Financial Guidance

Amicus Therapeutics reaffirmed its 2025 financial guidance, projecting total revenue growth between 15% and 22%, Galafold® revenue growth of 10% to 15%, and Pombiliti® + Opfolda® revenue growth of 50% to 65%. The company anticipates achieving GAAP profitability in the second half of 2025.